Big shot sidekick11/29/2023 Moderna said it expects combination vaccines to be available as soon as 2025. based on the current findings while Moderna conducts a larger study to confirm that the vaccine prevents disease symptoms.Īs sales for COVID shots wane, Moderna is working to expand its product portfolio and show that its technology will work against other diseases, including various respiratory viruses and cancer. The company didn’t provide details of the results, which haven’t yet been published in a scientific journal.Īn accelerated approval would allow the shot to be approved in the U.S. The new results, if confirmed, indicate the reformulation worked. The original formulation performed well against influenza A, the most common type of flu, but fell short of showing it was as good as traditional vaccines at provoking an immune response against influenza B, a less common type. Moderna’s mRNA flu shot was reformulated earlier this year after an initial large trial showed mixed results compared to existing vaccines. Analysts expect Moderna’s revenue to fall to about $7 billion this year. “This is going to be a $15-plus billion annual sales franchise forever,” Bancel said. In a few years, these combos should produce large annual sales, Moderna Chief Executive Officer Stephane Bancel said in an interview Wednesday on Bloomberg TV. The company is working on combination vaccines against flu and COVID – and potentially other respiratory diseases that could reduce the number of shots needed for broad protection. Moderna’s share decline this year adds urgency to its efforts. The flu data is in line with expectations and it’s likely Moderna files for regulatory approval by year’s end, analysts from Jefferies said in a note.ĭeveloping an influenza vaccine is important for Moderna as it seeks new sources of revenue as sales for COVID-19 shots fade amid pandemic fatigue. “Our goal would be to file very quickly” for accelerated approval in the U.S., Moderna president Stephen Hoge said in an interview, without offering a specific timeline.ĭepending on how much additional follow-up data regulators need, Moderna’s shot could be on the market as soon as next year’s fall-winter flu season, he said. The stock had declined 41% this year through Tuesday’s close. ![]() Moderna shares jumped as much as 9.2% in New York trading. The study looked at antibody levels against the flu and didn’t directly assess efficacy in preventing disease symptoms. Side effects were similar to previous trials of the vaccine. ![]() In a trial on over 2,400 adults, the reformulated shot produced a stronger immune response against all four strains of the influenza virus than a traditional flu vaccine, the company said in a statement Wednesday. ![]() Moderna said a reformulated version of its messenger-RNA based flu shot met its primary goals in a final-stage trial – a result that could pave the way for the company to seek regulatory approval for the influenza vaccine.
0 Comments
Leave a Reply.AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |